anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET and described the 5-year trajectories of quality of life (QoL) and symptoms in young women (≤40 years) with hormone receptor-positive breast cancer (BC).
METHODS: We retrieved data on clinical characteristics and non-persistence from the medical annual records in the European cohort of the "Helping Ourselves, Helping Others: The Young Women's BC Study" (IBCSG 43-09 HOHO). Women completed surveys at baseline, biannually for three years, and annually for another seven years. Data collection included sociodemographic information, QoL aspects assessed by the Cancer Rehabilitation Evaluation System-Short Form and symptoms assessed by the Breast Cancer Prevention Trial symptom scales. Cox regression models were applied to identify factors associated with non-persistence.
RESULTS: The cumulative risk of interrupting ET within 5 years was 27.7 % (95 % CI, 21.5-35.2). The QoL subscale scores remained stable over 5 years, with slight improvements in the physical subscale. Hot flashes decreased (p < 0.001), while vaginal problems intensified (p < 0.001) over time. Being married without children and having difficulties interacting and communicating with the medical team were significantly associated with non-persistence.
CONCLUSIONS: Discussing the desire to conceive with partnered childless women and establishing a good relationship with the medical team may be important in addressing the non-persistence in young BC survivors. As recent data suggests the safety of pausing ET to conceive, this approach may be a reasonable future option to limit non-persistence.
FIELD: medicine. SUBSTANCE: substance has hypohallite of alkaline metal of the general formula MeOX and halide of alkaline metal of the general formula MeX where Me - Li, K, Na, Rb, Cs and X - Cl, Br, J. This is a solid water-soluble substance. Method of preparing this substance involves preparing a mixture containing alkaline metal hypohallite and halide and water. Then mixture is frozen and kept under decreased pressure. Substance can be used as an antiseptic agent and for disinfection. EFFECT: improved method of preparing, enhanced effectiveness of substance. 4 cl, 3 dwg
PURPOSE: Hip osteoarthritis (OA) is a major cause of pain and disability worldwide. Lack of effective therapies may reflect poor knowledge on its aetiology and risk factors, and result in the management of end-stage hip OA with costly joint replacement. The Worldwide Collaboration on OsteoArthritis prediCtion for the Hip (World COACH) consortium was established to pool and harmonise individual participant data from prospective cohort studies. The consortium aims to better understand determinants and risk factors for the development and progression of hip OA, to optimise and automate methods for (imaging) analysis, and to develop a personalised prediction model for hip OA.
PARTICIPANTS: World COACH aimed to include participants of prospective cohort studies with ≥200 participants, that have hip imaging data available from at least 2 time points at least 4 years apart. All individual participant data, including clinical data, imaging (data), biochemical markers, questionnaires and genetic data, were collected and pooled into a single, individual-level database.
FINDINGS TO DATE: World COACH currently consists of 9 cohorts, with 38 021 participants aged 18-80 years at baseline. Overall, 71% of the participants were women and mean baseline age was 65.3±8.6 years. Over 34 000 participants had baseline pelvic radiographs available, and over 22 000 had an additional pelvic radiograph after 8-12 years of follow-up. Even longer radiographic follow-up (15-25 years) is available for over 6000 of these participants.
FUTURE PLANS: The World COACH consortium offers unique opportunities for studies on the relationship between determinants/risk factors and the development or progression of hip OA, by using harmonised data on clinical findings, imaging, biomarkers, genetics and lifestyle. This provides a unique opportunity to develop a personalised hip OA risk prediction model and to optimise methods for imaging analysis of the hip.
1,185,225. Sustained release injections. HAVER-LOCKHART LABORATORIES, Inc. 14 March, 1967 [1 April, 1966], No. 11968/67. Heading A5B. [Also in Division C3] A sustained release injectable adjuvant carrier for a medicinal agent comprises water and Type 2 collagen or Type 3 collagen or a mixture thereof. Type 2 collagen is prepared by mild acid treatment of a saline-extracted collagen source such as cartilage or bone; if the source is tendon, the saline extraction stage may be omitted. Type 3 collagen is obtained by allowing Type 2 to age until a required degree of polymerisation has taken place, to give an adjuvant with slower release properties than Type 2. The source materials are preferably defatted e.g. with ether, and subjected to trypsinisation, prior to the saline extraction. The latter is performed with 0.9% aqueous sodium chloride at room temperature for two hours. The acid treatment consists of standing the collagen source in 0.01M acetic acid at room temperature for several hours, when most of the collagen disperses into solution. The viscous solution is brought to a pH of 6.0 to 9.0, when a highly viscous sediment precipitates out; this product, which, after separation of the supernatant, contains 85 to 99% water, is the required adjuvant. It may be sterilised with a small quantity of formalin and admixed with a medicinal agent; the resulting composition sets to a gel in vivo after injection and provides a slow and sustained release of the medicament. Alternatively, the composition may be dried, e.g. by freeze-drying, and injected in the form of a solid filament. Suitable medicaments are immunological agents such as attenuated or killed viruses (e.g. equine encephalomyelitis, canine distemper), hormones or vitamins, especially vitamin A, or antibiotics. Pencillin and streptomycin also may be included as preservatives. An injectable vitamin A composition exemplified also contains a surface active agent (polysorbate 80), ethanol, cotton seed oil and soy bean oil.
RAD51 filament is crucial for the homology-dependent repair of DNA double-strand breaks and stalled DNA replication fork protection. Positive and negative regulators control RAD51 filament assembly and disassembly. RAD51 is vital for genome integrity but excessive accumulation of RAD51 on chromatin causes genome instability and growth defects. However, the detailed mechanism underlying RAD51 disassembly by negative regulators and the physiological consequence of abnormal RAD51 persistence remain largely unknown. Here, we report the role of the human AAA+ ATPase FIGNL1 in suppressing a novel type of RAD51-mediated genome instability. FIGNL1 knockout human cells were defective in RAD51 dissociation after replication fork restart and accumulated ultra-fine chromosome bridges (UFBs), whose formation depends on RAD51 rather than replication fork stalling. FIGNL1 suppresses homologous recombination intermediate-like UFBs generated between sister chromatids at genomic loci with repeated sequences such as telomeres and centromeres. These data suggest that RAD51 persistence per se induces the formation of unresolved linkage between sister chromatids resulting in catastrophic genome instability. FIGNL1 facilitates post-replicative disassembly of RAD51 filament to suppress abnormal recombination intermediates and UFBs. These findings implicate FIGNL1 as a key factor required for active RAD51 removal after processing of stalled replication forks, which is essential to maintain genome stability.
<P>PROBLEM TO BE SOLVED: To provide a coating-treated powder obtained by coating-treating a powder with a raw material derived from vegetable oil-and-fat that has no concern about generation of offensive odor with the lapse of time, can be incorporated with a cosmetic, has a very smooth touch feeling and is excellent in water repellency and pigment dispersibility, and to provide a cosmetic comprising the coating-treated powder.  <P>SOLUTION: The coating-treated powder is obtained by coating-treating a powder to be treated with a mixture, as a coating-treating agent, comprising 60-90 wt.% of an extremely hardened vegetable oil-and-fat having a melting point of 50°C or higher and 10-40 wt.% of an ester oil agent derived from vegetable oil-and-fat. Preferably, the powder is coating-treated at a temperature 10-20°C higher than the melting point of the extremely hardened vegetable oil-and-fat when coating-treated with the coating-treating agent. The powder to be treated is coating-treated with the coating-treating agent in an amount of preferably 1-15 wt.%, particularly preferably 3-10 wt.%. The cosmetic is obtained by using the coating-treated powder as a part or the whole of components thereof.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE:A polishing composition having a proper polishing ability and good feeling in use, capable of preventing scratch, comprising a specific aluminum hydroxide as a polishing agent. CONSTITUTION:A toothpaste composition comprising 1-70wt%, preferably 30- 50wt% of an aluminum hydroxide as a polishing agent, having an average particle size of 5-14mu, a content of adhered sodium oxide not more than 0.02wt%, a pH of 10wt% slurry of 7-9, and a Hunter whiteness not less than 96%. The abrasion and scratch of the teeth will not occur, the teeth can be expected fully to become clean, the composition has neither rough nor viscous touching but gives good touching to the tongue. It has neither odd flavor nor puckery taste, but has a good taste. The toothpaste composition will not corrode a tube, can be stored for a long period of time, and the lowering of its quality will not nearly occur. It has a high whiteness, good appearance, and provides users with a fine feeling.
Provided are a system and method for an artificial pancreas having multi-stage model predictive control to minimize and/or prevent occurrence of hypoglycemia associated with Type 1 diabetes. The control implements predictive modeling of a probability of glucose uptake associated with exercise based on at least one exercise profile for a subject with Type 1 diabetes. Based on the probability, the control implements an automatic adjustment of basal insulin infusion to counteract a risk of exercise-induced hypoglycemia in advance of the subject engaging in the exercise. The control implements adjustment of such infusion based on real-time signaling of exercise likely to induce hypoglycemia. The control implements adjustment of a meal-time bolus to account for delay in glucose uptake resulting from exercise engaged in by the subject. Consequently, the control acts to minimize and/or prevent hypoglycemia from occurring both during and immediately after exercise.
OBJECTIVE: Age-related changes in the fiber structure around adipocytes were investigated via scanning electron microscopy (SEM) of excised skin tissues. In addition, the viscoelasticity of the subcutaneous fat layer was evaluated via elastography, and the association between the fiber structure and the viscoelastic properties was assessed.
METHODS: Skin tissues excised from the facial cheek area were used. Then, SEM images of these tissues were obtained. The thickness and quantity of the fibers around adipocytes were assessed using a 5-point scale. The score was used to grade 18 tissue samples. Moreover, the viscoelasticity of the subcutaneous fat layer in the same samples was evaluated via ultrasound elastography.
RESULTS: Based on the SEM image score, an association was observed between the fiber status score and age, thereby indicating a tendency toward age-related fibrosis. Fiber structures with high scores, which indicate fibrosis, had a significantly lower viscoelasticity based on ultrasound elastography.
CONCLUSION: The thickness and quantity of fibrous structures around adipocytes in the subcutaneous fat layer increase with age, and these changes can be associated with decreased viscoelasticity in the subcutaneous fat layer.
BACKGROUND: Surgical resection is the gold standard treatment for the management of early-stage lung cancer. Several modifiable factors may significantly influence postoperative morbidity and mortality. We examined the outcomes of patients following lung resection based upon preoperative smoking status to quantify the impact on postoperative outcomes.
METHODS: Data from consecutive lung resections from January 1, 2012 to June 11, 2021 were included. Biopsies for interstitial lung disease and resections for emphysematous lung or bullae were excluded. Patients were divided into three cohorts: current smokers (those who smoked within 4 weeks of surgery), ex-smokers (those who stopped smoking prior to 4 weeks leading up to surgery), and nonsmokers (those who have never smoked). Patient's preoperative variables, postoperative complications, length of stay, and mortality were examined.
RESULTS: A total of 2,426 patients were included in the study. A total of 502 patients (20.7%) were current smokers, 1,445 (59.6%) were ex-smokers and 479 patients (19.7%) nonsmokers. Of those smoking immediately prior to surgery 36.9% developed postoperative complications. Lower respiratory tract infections (18.1%) and prolonged air leak (17.1%), in particular, were significant higher in smokers. 90-day mortality (5.8%) was higher in the current smokers when compared with ex- and nonsmokers (5.3 and 1%, respectively). Median length of hospital stay, readmissions, and cost of hospital stay was also higher in the current smoker cohort.
CONCLUSION: Smoking immediately prior to surgery is associated with an increase in morbidity, mortality, and length of stay. Not only does this have a significant individual impact, but it is also associated with a significant financial burden to the National Health Service.
Patients with PD have exceptionally poor sleep. Sleep in patients with PD is characterized by excessive activity in surface electromyographic (EMG) recordings from many different muscle groups. Despite sleep disturbances, approximately 50% of patients experience a transient (1 to 3 hour) reduction in waking motor symptoms upon arising in the morning. This effect has been termed Sleep Benefit. This study will evaluate the effects of valerian, a medicinal herb, on the sleep of patients with PD.

This is a 17 day study where participants will be evaluated by polysomnography on days one, two, three, sixteen and seventeen.. Polysomnographic measurements will include customary variables such as total sleep time, sleep efficiency, and sleep latency, as well as EMG measures of periodic and isolated muscle activity during sleep. Participants will be required to keep a detailed sleep log of their self reported sleep characteristics across the entire 17 study nights. Outcomes will include measures of both nocturnal sleep and waking motor function. Assessments of motor function will be made the morning immediately following Nights 3 and 17 in order to test for improvement related to improved sleep. On the morning following Night 17, participants are provided with a one-week supply of valerian in an Open Label extension. Participants are provided an additional Sleep Log for this week and asked to return the Sleep Log when they complete the Open Label phase.
Polar angle asymmetries (PAAs), the differences in perceptual experiences and performance across different regions of the visual field are present in various paradigms and tasks of visual perception. Currently, research in this area is sparse, particularly regarding the influence of PAAs during perceptual illusions, highlighting a gap in visual cognition studies. We aim to fill this gap by measuring PAAs across the visual field during an illusion applied to test conscious vision widely. Motion-induced blindness (MIB) is an illusion when a peripheral target disappears from consciousness as the result of a continuously moving background pattern. During MIB we separately measured the average disappearance time of peripheral targets in eight equidistant visual field positions. Our results indicate a significant variation in MIB disappearance times and frequencies as a function of target location. Specifically, we found shorter and fewer disappearances along the cardinal compared to oblique directions, and along the horizontal compared to the vertical meridian. Our results suggest specific consistencies between visual field asymmetries and conscious visual perception.
PURPOSE: The aim of this study was to describe the direct immunofluorescence (DIF) findings and factors affecting conjunctival biopsy positivity in patients clinically diagnosed with ocular mucous membrane pemphigoid (OMMP).
METHODS: This retrospective observational case series included patients with clinical OMMP who underwent conjunctival biopsy for DIF in at least 1 eye between 2018 and 2021 in an institutional setting. The primary outcome measures were association of age and chronic ocular complications with biopsy positivity.
RESULTS: Of 61 patients, DIF positivity was seen in 33 (54.1%) clinically suspected cases of OMMP. Of 39 patients who underwent bilateral biopsy, 23 (59%) were positive, of which 12 (52%) were positive in both eyes while 11 (48%) were positive in 1 eye. Of 22 patients who underwent unilateral biopsy, 10 (45%) were positive. Of the 100 biopsied eyes, 45 (45%) were DIF positive. Among the immunoreactants studied, linear deposition of C3 was seen in all 45 positive eyes (100%). Increasing age was significantly associated with higher likelihood of biopsy negativity ( P = 0.032), whereas a greater Sotozono chronic ocular complication score, indicative of disease severity, was associated with low likelihood of biopsy positivity ( P = 0.0042) and lower overall expression of immunoreactants on DIF ( P = 0.0007).
CONCLUSIONS: Older patients and patients with more severe ocular surface disease sequelae are likely to have negative DIF results. To optimize the chances of confirming the diagnosis of OMMP by DIF, both eyes should be biopsied early in the disease course. If 1 eye is being biopsied, the less affected eye must be chosen.
To improve patient stratification, the investigators have developed a panel of novel circulating liver specific and mechanistic biomarkers that report early acute liver injury. Such biomarkers are needed as current early biomarkers of liver injury lack sensitivity and specificity. The panel of biomarkers either have enhanced liver specificity or provide mechanistic insights. Currently, antituberculosis drug-induced liver injury (ATDILI) is the most frequent side-effect of anti-tuberculosis therapy and this hinders the effective treatment of TB, as it means that treatment regimens are not completed. At present, the risk of ATDILI means that monitoring of liver function is required, with levels of ALT measured monthly. If levels of ALT rise to 2-5x the upper limit of normal levels (ULN) and the patient is unwell the frequency of monitoring is increased to biweekly monitoring. Antibiotic therapy is only changed if levels of ALT remain greater than 3xULN, the patient continues to display symptoms and there is a positive causality assessment that the anti-tuberculosis drugs are causing ATDILI. This project will recruit patients taking antituberculosis drugs and determine the diagnostic and prognostic value of the biomarker panel, in relation to liver injury as a result of anti-tuberculosis therapy.
BACKGROUND: Okur-Chung neurodevelopmental syndrome (OCNDS) is a rare autosomal dominant disorder caused by pathogenic variants in CSNK2A1. It is characterized by intellectual disability, developmental delay, and multisystemic abnormalities.
METHODS: We performed the whole-exome sequencing for a patient in a Chinese family. The co-segregation study using the Sanger sequencing method was performed among family members. Reverse transcription and quantitative real-time polymerase chain reaction were carried out using total RNA from blood samples of the proband and wild-type control subjects. A review of patients with OCNDS harboring CSNK2A1 pathogenic variants was conducted through a comprehensive search of the PubMed database.
RESULTS: We identified a novel CSNK2A1 frameshift variant p.Tyr323Leufs*16 in a Chinese family. The proband, a 31-year-old female, presented with abnormal eating habits, recurrent seizures, language impairment, and intellectual disability. Her mother exhibited postnatal hernias, splenomegaly, and a predisposition to infections, but showed no significant developmental impairments or intellectual disability. Genetic studies revealed the presence of this variant in CSNK2A1 in both the proband and her mother. Transcription analysis revealed this variant may lead to nonsense-mediated mRNA decay, suggesting haploinsufficiency as a potential disease mechanism. We reviewed 47 previously reported OCNDS cases and discovered that individuals carrying CSNK2A1 null variants may exhibit a diminished frequency of symptoms linked to language deficits, dysmorphic facial features, or intellectual disability, consequently presenting an overall milder phenotype when compared to those with missense variants.
CONCLUSION: We report a novel frameshift variant, p.Tyr323Leufs*16, in an OCNDS family with a generally mild phenotype. This study may broaden the spectrum of clinical presentations associated with OCNDS and contribute novel insights into the genotype-phenotype correlation of this condition.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety assessment is based on all data from 1203 subjects in the Phase 3 placebo-controlled trials, TMC125-C206 and TMC125-C216, conducted in antiretroviral treatment-experienced HIV-1-infected adult subjects, 599 of whom received INTELENCE® (200 mg b.i.d.). In these pooled trials, the median exposure for subjects in the INTELENCE® arm and placebo arm was 52.3 and 51.0 weeks, respectively. Discontinuations due to adverse drug reactions (ADRs) were 5.2% in the INTELENCE® arm and 2.6% in the placebo arm.

The most frequently reported ADR at least Grade 2 in severity was rash (10.0%). Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in < 0.1% of subjects during clinical development with INTELENCE® [see Warnings and Precautions (5.1)]. A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving INTELENCE® discontinued due to rash. In general, in clinical trials, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4. Rash generally resolved within 1-2 weeks on continued therapy. The incidence of rash was higher in women compared to men in the INTELENCE® arm in the Phase 3 trials. Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE®-related rash compared to patients without a history of NNRTI-related rash.
Abstract of the Disclosure Anti-tumor   activity   in  mammals  can  be  augmented  by administering to the mammalian host a synergistically effective amount of TNF and  IL-2 or of TNF and IFN-.beta., or of TNF,  IL-2 and IFN-.beta. in combination.   The  composition of TNF and  IL-2 and/or  IFN-.beta. may be prepared in vitro or administered separately to the host.  If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy.   The composition is useful  for treating  such  cancers  as  mastocytoma,  melanoma,  leukemia,  and lymphoma.